Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Backers
1
Oak Investment Partners
Momentum
0/100
no fresh signals
Backed byfrom the funds' portfolios and accelerator catalogs
Similar startupsby what they do, their industry and backers
Odyssey is on a mission to transform the standard of care for patients affected by autoimmune and inflammatory conditions.
Octagon TherapeuticsVenture round $11M · 2 yr ago • Founded 2016 • 11-50 employees
A biotech company developing better medicines for patients with autoimmune and inflammatory diseases. Leveraging powerful insights into the…
Quell Therapeutics is a clinical-stage company, fuelled by curiosity and discovery, on a mission to make life better for those battling…
Company Management Team Board of Directors Scientific Advisory Board Clinical Advisory Board Company History Investors Science Biology…
cAMPfield TherapeuticsFounded 2026 • 3 roles
CAMPfield Therapeutics is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor…
We believe that clinical remission should be the standard—not the exception—for treating chronic inflammatory diseases like COPD, asthma…

Overview

Quercis Pharma develops Kinisoquin™, a first-in-class oral PDI inhibitor in Phase 3 for the prevention of cancer-associated thrombosis, sickle cell disease and other thrombo-inflammatory conditions.